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1. INTRODUCTION 
1.1. Allergic contact dermatitis 
Allergic contact dermatitis (ACD) is a common inflammatory skin disease in industrialized 
countries with a great socio-economic impact. It is one of the most common occupational 
diseases. In Europe about 20% of the general population suffers from contact allergy to at least 
one contact allergen. Most common are allergies to nickel, fragrances and preservatives. 
Allergic reactions to chromate and p-phenylenediamine (PPD) are generally less common but 
occur frequently in occupationally exposed subgroups of the population (Lunder et al., 2000). 
Risk factors for allergic contact dermatitis (ACD) can be subdivided into acquired and inherent. 
Acquired risk factors are generally inflammatory skin diseases such as irritant contact dermatitis 
(ICD) and possibly atopic dermatitis, while inherent risk factors are genetic variances resulting 
in a higher susceptibility.  
It is initiated when allergens, usually haptens, penetrate the skin and modify the host’s structural 
proteins. The contact allergen activates dendritic cells (DCs) in the skin via ‘pattern recognition 
receptors’ such as TLRs. Subsequently naїve T helper (Th) cells are polarised upon specific 
recognition of the haptenated allergen by the major histocompatibility complex (MHC), co-
stimulatory signals and cytokines such as IL-12, IL-4, IL-1b and IL-6; polarized cells are 
conveyed to the draining lymph nodes where they undergo activation and clonal expansion 
(Gober et al., 2008). The lymphocytes thus activated then migrate to the peripheral tissue ready 
for subsequent encounter with the same antigen. In the elicitation phase, following re-exposure 
of the skin to the same contact allergen, hapten-specific cytotoxic CD8+ T lymphocytes (CTLs) 
release inflammatory cytokines and induce disease-specific local symptoms such as redness, 
papules and vesicles (Gober et al., 2008) (Figure 1). 
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Figure 1. Lymphocyte-mediated immune mechanisms in contact allergy. 
 
 
Thus, during the rapidly triggered innate immune response to contact allergens, among others, 
keratinocytes, mast cells and DCs are activated, and NK cells and neutrophils are recruited. 
Mast cells increase vascular permeability, thereby facilitating the recruitment of innate 
inflammatory cells. It has also been shown that mast cells contribute to the recruitment of 
leukocytes via TNF-α and support skin DCs maturation, migration and polarization of T-cell 
responses to IL-17 and IFN-γ production (Biedermann et al., 2000, Kneilling et al., 2009 
Cumberbatch et al.,  201 Dudeck et al.,  2011). 
1.2. The Interleukin-1 family 
Interleukin-1 (IL-1), which as its name suggests was the first interleukin to be described, 
possesses many biological activities. Indeed, before its molecular identification in the mid 
1980s, IL-1 had actually been studied for many years under various names (such as leukocyte 
endogenous mediator, haematopoietin 1, endogenous pyrogen, catabolin and osteoclast 
activating factor) that describe the multiple and varied biological functions of this cytokine. 
Over the past decade, several other members of the IL-1 family have been identified, and their 
important roles in innate and adaptive immune responses have been revealed. This family 
comprises 11 members with both pro- and anti-inflammatory activities. In 2009, a dramatic 
increase was observed in the number of publications on the function and potential disease 
involvement of the IL-1 family members. (Sims et al., 2010) 
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IL-1α (also termed IL-1F1) and IL-1β (IL-1F2) bind both to IL-1RI, whereas IL-1Ra (IL-1F3) 
has an antagonistic effect on this receptor. These cytokines play an important role in immune 
regulation and inflammatory processes by inducing expression of many effector proteins, e.g. 
cytokines/chemokines (Dinarello, 2011). Excessive and/or dysregulated activity of these 
mediators is associated with tissue destruction and therefore the synthesis, secretion and 
biological activity of IL-1 cytokines have been identified as therapeutic targets for common 
inflammatory disorders such as rheumatoid arthritis (RA) (Burger et al., 2006). 
IL-18 (IL-1F4) binds to IL-18Rα with a pro-inflammatory activity. IL-18 is important in both 
innate and acquired immune responses; it stimulates neutrophil migration and activation as well 
as T helper 1 (Th1) cell differentiation and interferon (IFN)-γ secretion in a variety of cell types. 
IL-18 has a role in destructive inflammatory disorders (Gracie et al., 2003) and is a potential 
therapeutic target although, currently, anti-IL-18 therapies are only at the preclinical trial stage 
(Anderson et al., 2006). 
IL-36α, IL-36β and IL-36γ (originally named IL-1F6, IL-1F8 and IL-1F9, respectively) bind to 
the IL-36 receptor (IL-36R, also named IL-1Rp2 or IL-1RL2) and a pro-inflammatory signal is 
initiated, whereas IL-36Ra, also termed IL-1F5, acts as the natural-occurring receptor 
antagonist. Similar to the classical IL-1 cytokines, IL-36α, IL-36β and IL-36γ are also involved 
in the initiation or regulation of immune responses (Sims et al., 2010). Differently from IL-1α 
and IL-1β, IL-36α, IL-36β, IL-36γ and IL-36Ra are expressed in a restricted manner, primarily 
in the skin and other epithelial tissues, whereas the receptors are more widely expressed (Sims et 
al., 2010). 
IL-1F7 acts as an attenuator of IL-18 activity (Pan et al., 2001) and may act as an inhibitor of 
innate immune signaling. 
IL-1F10 has been reported to bind soluble IL-1R1 to unknown effect. It has been shown to be 
expressed in the basal epithelium of skin and by proliferating B cells in tonsil germinal centres 
(Lin et al., 2001). The genomic structure and amino acid sequence of IL-1F10 both indicate a 
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closer relationship to IL-1Ra and IL-36Ra than to the rest of the family, suggesting it may have 
an antagonistic role.  
IL-1F11 is also known as IL-33; it binds to ST2 receptor and a pro-inflammatory activity is 
started. From studies using soluble forms of ST2 or antibodies to ST2, we know that IL-33 
drives T helper type 2 responses (Schmitz et al., 2005). 
1.3. The IL-1 family and immune-mediated diseases 
The key role of IL-1 family members in driving T cell, B cell and innate immune cell responses 
inevitably makes them important contributors to immune mediated diseases. 
IL-18 is implicated in the pathogenesis of arthritis. Excessive production of IL-18 is found in 
both blood and inflamed joints of patients with rheumatoid arthritis. moreover, therapeutic 
inhibition of IL-18 alleviates disease in animal models of arthritis, often coincident with 
reductions in synovial IL-1 and TNF-α levels (Gabay et al., 2009). However, the result of 
effective inhibition of human IL-18 in patients with rheumatoid arthritis has not been reported. 
Conversely, inhibition of IL-1 not only stops further disease progression but also reverses 
established disease and is more effective than inhibition of TNF-α (Joosten et al., 1999). 
However, the therapeutic use of the recombinant form of IL-1Ra, Anakinra (Kineret; 
Amgen/Biovitrum), in rheumatoid arthritis has yielded disappointing results, with fewer patients 
benefiting and higher disease scores than inhibitors of TNF-α or biologics (Mertens et al., 
2009). 
Both IL-1α and IL-1β expression are enhanced in the inflamed intestinal mucosa of patients 
with inflammatory bowel disease, whereas IL-1Ra is only modestly increased, resulting in a 
significant decrease in the ratio of IL-1Ra to IL-1 (Casini-Raggi et al., 1995). Inhibition of IL-1 
is beneficial in several models of inflammatory bowel disease.  The mechanism by which low 
levels of IL-1 secretion contributes to the pathology of Crohn’s disease has not been identified 
but could relate to the hypothesis that the disease is in part caused by a dysfunctional mucosal 
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innate immune system, resulting in inadequate initial responses to infection or tissue damage 
(Yamamoto-Furusho et al., 2006). 
Asthma is a syndrome of reduced airway flow and bronchial remodelling that is driven in part 
by unregulated and excessive pulmonary inflammation. The expression of IL-1β by 
macrophages in the alveoli and airway submucosa is increased in patients with asthma. In mouse 
models of airway inflammation provoked by either a protein (ovalbumin) or a small molecule 
(toluene diisocyanate) allergen, both IL-1α and IL-1β are required for full development of 
disease, including eosinophil infiltration into the lung, goblet cell hyperplasia, adhesion 
molecule expression, production of IL-4, IL-5 and allergen-specific IgG and Ige antibodies, and 
airway hyperresponsiveness (AHR). IL-1Ra administered at the allergen challenge phase 
reduces inflammation and AHR in response to ovalbumin (Wang et al., 2006). Moreover, 
although IL-18 is thought to be a Th1-type cytokine, multiple lines of evidence suggest it is a 
contributing factor in asthma. 
IL-1 family members are abundantly expressed in the skin. Psoriasis is a common disease 
characterized by abnormal epidermal differentiation that leads to redness and scaling of the skin. 
It is thought to be driven by Th-1 and Th-17 cells, although there is also an epidermal 
component (Lowes et al., 2007). IL-1 family members are increased in the skin lesions of 
patients with psoriasis (Naik et al., 1999, Zhou et al., 2003, Blumberg et al., 2007), and in 
particular their expression can be induced by pro-inflammatory stimuli and suppressed by anti-
inflammatory Retinoic acid and vitamin D (Balato et al., 2013). In particular, a recent study 
demonstrated that IL-36Ra, IL-36α, IL-36β and IL-36γ are able to drive antimicrobial peptides 
expression in skin and generate a psoriasis-like gene expression profile (Jhonston et al., 2011). 
In addition, these cytokines are not only effector cytokines downstream of their induction by Th-
17 cytokines in the skin, but also inducers of many pro-inflammatory mediators that regulate 
cellular and soluble components of the local inflammatory milieu (Carrier et al., 2011).  
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1.4. IL-1 family and allergic contact dermatitis 
Serveral cytokines, including members of the IL-1 family, play a fundamental role in the 
sensitization, elicitation and resolution phases of experimental contact hypersensitivity reactions 
(Kawase et al., 2003, Antonopoulos et al., 2008, Christensen et al., 2012).  
Langerhans cells produce IL-1β and IL-18 following activation by allergens. IL-1β and IL-18 
upregulate the expression of co-stimulatory molecules by Langerhans cells and enable their 
migration out of the skin to the draining lymph node, where they can present antigen effectively 
to T cells. IL-18 also promotes contact hypersensitivity, and inhibition of IL-18 in rodents 
alleviates ongoing dermatitis (Plitz et al., 2003). IL-1 and IL-18 contribute to T cell activation 
and recruitment to skin lesions (Wang et al., 2002). Many contact sensitizers can activate the 
inflammasome in keratinocytes, leading to the production of both IL-1 and IL-18, and contact 
hypersensitivity reactions are defective in mice that lack any of several inflammasome 
components (Watanabe et al., 2007).  
IL-1α and IL-33 are known to be involved in contact hypersensitivity (Komai-Koma et al., 
2011, Nakae et al., 2001). IL-1 is involved in the early inflammatory events, occurring within 
hours after sensitization, which dictate the development and severity of ACD (Bonneville et al., 
2007). Genetic susceptibility contributes to differences in host sensitivity to allergens and 
patients who have IL-1Ra gene polymorphism are prone to less effective antagonism to pro-
inﬂammatory cytokine IL-1 (Ertam et al., 2009). In addition, IL-18 has been shown to be a 
mediator of ACD both in human and murine models (Gangemi et al., 2003, Corsini et al., 2009, 
Zhang et al., 2010). 
IL-33 may play a role in the activation of these B1 B cells in ACD (Komai-Koma et al., 2011). 
These cells are required especially in the early phase of the elicitation of ACD, by producing 
IgM which induces T-cell recruitment. IL-33 also activates mast cells and plays a role in 
neutrophil recruitment (Hueber et al., 2011), thereby providing a further link between the 
different immune players.  
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The possible role of new IL-1 family members in the skin of patients with ACD is poorly 
understood. To better define the role of this family in skin inflammation, we obtained biopsies 
of normal donors, uninvolved and involved ACD skin and assessed the expression of IL-1β, IL-
1Ra, IL-36s and IL-33 by real-time PCR, which we extended by immunohistochemical 
evaluation.    
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2. MATERIALS AND METHODS 
2.1. Human subjects  
The study population consisted of 25 subjects (mean age: 45.3 ± 2.7 years) with at least one 
positive reaction to patch test (Table 1). The intensity of reactions was evaluated according to 
the guidelines of the Italian Society of Allergic Dermatology (SIDAPA) in line with the 
recommendations of the International Contact Dermatitis Group (Fregert, 1981). Results were 
recorded as negative, doubtful, weakly positive (1+), moderate reaction (2+) and strong reaction 
(3+). The experimental protocols were approved by the Ethics Committee of the University of 
Naples Federico II and conformed to the principles outlined in the Declaration of Helsinki. Each 
subject gave written informed consent before entering the study. 
2.2. In vivo expression of IL-1 family members in ACD 
Skin biopsies (3 mm each) from involved and uninvolved sites (clinically normal skin) were 
taken from subjects with at least one positive reaction to patch test, and used for in vivo mRNA 
examination through real-time PCR. Skin specimens from normal donors (control) who had 
undergone plastic surgery and without a history of contact sensitization served as controls. 
2.3. Immunohistochemical detection of IL-1 family members in ACD 
The immunohistochemical detection of IL-1 family members was carried out on the skin 
biopsies from the eczematous lesion of ACD patients and from controls. Skin samples were 
immediately placed in tissue freezing medium (Jung, Leica, Wetzlar, Germany) and stored at 
−80° C. Five micrometer sections were cut with a cryostat and fixed with cold acetone for 10 
min. The Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA) was used as follows: 
sections were incubated with blocking solution (horse serum diluted in buffer: phosphate 
buffered saline  [PBS] + bovine serum albumin 1%) for 20 min at 22° C. Biopsies were stained 
with mouse anti-human IL-33 (0.5 µg/ml, clone Nessy-1, Alexis Biochemicals, San Diego, CA), 
IL-36Ra (5 µg/ml R&D System Inc., Minneapolis, MN), IL-36β (5 µg/ml R&D System Inc.) or 
goat anti-human IL-36α (15 µg/ml R&D System Inc.), IL-36γ (15 µg/ml R&D System Inc.) and 
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incubated overnight at 4° C. The sections were then washed in buffer and incubated with 
biotinylated secondary antibody for 30 min at room temperature. Peroxydase activity was 
revealed using DAB substrate (ImmPACT DAB, Burlingame, CA). Counterstaining was 
performed with hematoxylin.  
2.4. Ex vivo expression of IL-1 family members in ACD 
Skin biopsies (3 mm, each) from uninvolved skin of subjects affected by ACD were obtained for 
ex vivo assays. Skin specimens obtained from normal donors were used as controls. Biopsies 
were cultured as follows: a hole was punched in a transwell filter (pore size 1 µm; Beckton 
Dickinson Labware, Franklin Lakes, NJ). The biopsy was inserted into the hole, and the filter 
containing the biopsy was placed in a 12-well culture plate (Beckton Dickinson Labware) 
containing 1 ml of Dulbecco’s modified Eagle’s medium (DMEM, GIBCO, Grand Island, NY) 
containing 10% FBS (GIBCO), 2 mM L-glutamine (GIBCO) and antibiotics (100 IU/ml 
penicillin G, 100 µg/ml streptomycin, GIBCO) (Trowell, 1954). In this system the epidermis 
faces upwards at the liquid-air interface whereas the dermis is suspended in the culture medium. 
The tissue was incubated at 37° C in a humidified atmosphere containing 5% CO2. Cultured 
uninvolved skin biopsies were exposed to the allergens that had previously elicited the positive 
patch test reaction and the vehicle only (petrolatum) as control. The same allergens were applied 
to cultured normal skin specimens and left in contact for 72 h at 37° C. The quantity of allergens 
used for these assays (30 mg) was the same used for the patch tests.  
2.5. Ex vivo exposure to the irritant sodium dodecyl sulphate  
Skin biopsies (3 mm, each) obtained from normal donors were used for irritation assays and 
exposed to the irritant compound sodium dodecyl sulphate (SDS) and to vehicle (H2O). The 
irritation assay was performed as follows: IQ chamber filter paper discs (Chemotechnique 
diagnostics, Velling, Sweden), impregnated with 25 µl of non-cytotoxic concentrations of SDS 
(2 mM and 4 mM) (Sigma Chemical Co., St. Louis, MO) and vehicle (H2O), were applied 
topically to the upwards surface of cultured skin for 72 h at 37° C (Ouwehand et al., 2010).  
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2.6. Ex vivo anti-inflammatory activity of IL-36Ra 
Skin biopsies (3 mm, each) from uninvolved skin of subjects affected by ACD were obtained in 
order to test IL-36Ra anti-inflammatory activity in ex vivo assays. Biopsies were cultured and  
treated with the corresponding sensitizing allergens as described above. Fifty microliters of 
recombinant IL-36Ra (rIL-36Ra; 1.25 µg/mL, R&D System, Inc.) were injected into the 
specimens and vehicle only (PBS) was injected into the remaining tissues as controls.   
2.7. Nickel stimulation of peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMC) were isolated from adult healthy volunteers with 
no history of contact allergic reactions and from patients with nickel contact allergy by density 
gradient centrifugation over Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden). They were 
then cultured in Roswell Park Memorial Institute medium (RPMI, GIBCO), supplemented with 
antibiotics (100 IU/ml penicillin G, 100 µg/ml streptomycin, GIBCO) and 10% fetal bovine 
serum (FBS, GIBCO), at a concentration of 2 x106 in 12-well plates. Cells were stimulated with 
NiSO4 (10-5 M) and incubated at 5% CO2 at 37° C.  
2.8. Immunohistochemical detection of IL-33 after exposure to sodium dodecyl sulphate 
Skin specimens obtained from 5 normal donors who had undergone plastic surgery and with no 
history of contact sensitization were exposed to the irritant compound SDS and used for IL-33 
immunohistochemical analysis that was performed as described above. 
2.9. Ex vivo activity of IL-33 
Skin biopsies from uninvolved skin of 5 subjects affected by ACD, were obtained in order to 
test IL-33 activity through ex vivo assays. Biopsies were cultured and treated with the 
corresponding sensitizing allergens as described previously. Fifty microliters of anti-IL-33 
polyclonal antibody (0.2 µg/mL, Abcam, Cambridge, UK) were injected into the specimens, 
whereas the vehicle only (PBS) was injected into the remaining tissues as controls.  
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2.10. RNA extraction, cDNA synthesis and real-time polymerase chain reaction  
RNA was extracted from skin biopsy specimens (RNeasy Mini Protocol Qiagen) and cDNA was 
prepared (Transcriptor High Fidelity cDNA Synthesis, Roche, Indianapolis, IN) according to the 
manufacturer’s instructions. PCR (LightCycler, Roche, Indianapolis, IN) was used to analyze 
the levels of expression of 18S, IL-1β, IL-1Ra, IL-36Ra, IL-36α, IL-36β, IL-36γ, IL-33, IL-8 
and monocyte chemoattractant protein-1 (MCP-1/CCL2). PCR primers for the selected genes 
were designed based on published sequences, and their specificity was verified with BLAST 
alignment search. To confirm amplification of the expected size fragment, amplification 
products were characterized by agarose gel electrophoresis. Melting curve analysis was carried 
out after completion to confirm the presence of single amplified species. Relative mRNA 
expression levels were normalized to the expression of 18S. 
2.11. Statistical analyses 
Statistical analyses were performed using GraphPad Prism 4.0 (GraphPad Software Inc, La 
Jolla, CA). Student’s t test was used to calculate statistical differences. Values of p<0.05 were 
considered significant. 
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3. RESULTS 
3.1. In vivo expression of IL-1 family members in ACD 
Given the pro-inflammatory nature of IL-1α and IL-1β, the identification of new members of the 
IL-1 family raised intriguing possibilities about their involvement in skin inflammation. Thus, 
we examined the constitutive expression of IL-1 family members using PCR in the sites of a 
positive patch test reaction (Involved), uninvolved skin (Uninvolved) of ACD patients, and in 
skin from normal donors (control) (Fig. 2). The expression of IL-1β (p<0.01) , IL-1Ra (p<0.01), 
IL-36α  (p<0.001), IL-36β (p<0.01), IL-36γ (p<0.01) and IL-33 (p<0.001) was significantly 
higher in involved skin of ACD patients than in skin from normal donors. Similarly, the 
expression of IL-1Ra (p<0.01) and IL-36γ  (p<0.01) was significantly higher in uninvolved 
ACD skin than in control skin. By contrast, the expression of anti-inflammatory IL-36Ra 
cytokine in involved and uninvolved skin did not differ from that in control skin. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. mRNA expression of IL-1 family members in skin biopsies of control skin from normal donors (Control), 
positive reaction to patch test (Involved) and from uninvolved skin (Uninvolved) of ACD patients. PCR values 
expressed relative to the housekeeping gene 18S. Data are displayed as boxes with the top and bottom representing 
the 25th and 75th percentiles, respectively. The line in the box represents the median and whiskers representing min 
and max. Error bars are not indicated when too small to depict. *p<0.05; **p<0.01; ***p<0.001.  
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3.2. Immunohistochemical detection of IL-1 family members in ACD 
To extend the previous results, we evaluated the immunohistochemical expression of IL-36Ra, 
IL-36α, IL-36β, IL-36γ and IL-33 in healthy and ACD lesional skin (Fig. 3). IL-36Ra protein 
levels did not differ between lesional skin and skin from normal donors. Compared with control 
skin, IL-36α was up-regulated in the spinous layers, IL-36β was up-regulated in suprabasal 
layers, whereas IL-36γ was up-regulated in all epidermal layers of lesional skin. IL-33 was up-
regulated in the basal layers and papillary dermis of ACD eczematous lesions.  
 
 
Figure 3. Immunohistochemical detection of IL-36Ra, IL-36α, IL-36β, IL-36γ and IL-33 in eczematous lesion of 
ACD patients and skin from normal donors (Control). Images X250 magnification.  
 
3.3. Ex vivo expression of IL-1 family members in ACD 
Given the overexpression of IL-1β, IL-1Ra, IL-36α, IL-36β, IL-36γ and IL-33 mRNA in 
positive patch test reaction sites, we examined whether these cytokines were increased in an ex 
vivo model of ACD. Uninvolved skin of ACD patients and skin from normal donors was 
cultured in a transwell system (Trowell, 1954). The skin tissue was placed in a filter with the 
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epidermis facing upwards at the liquid-air interface. The skin surface was exposed to the 
specific allergen that had previously elicited the positive patch test reaction or to the vehicle 
(petrolatum) as a control. Skin tissues obtained from normal donors were exposed to the specific 
allergen or vehicle. The vehicle did not increase the mRNA expression of any of the interleukins 
examined (Fig. 4). By contrast, allergen challenge of uninvolved skin of ACD patients 
significantly increased the mRNA expression of all interleukins examined except IL-36Ra. The 
effect was specific since allergen challenge did not affect control skin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. mRNA expression of IL-1 family members in skin from normal donors exposed to the vehicle (Normal 
skin + vehicle), uninvolved skin of ACD patients exposed to allergen (Uninvolved + allergen) and normal skin 
exposed to allergen (Normal skin + allergen). PCR values expressed relative to the housekeeping gene 18S. Data 
are displayed as boxes with the top and bottom representing the 25th and 75th percentiles, respectively; the line in 
the box represents the median and whiskers representing min and max. Error bars are not indicated when too small 
to depict.*p<0.05; **p<0.01; ***p<0.001.  
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3.4. Ex vivo exposure to sodium dodecyl sulphate 
Skin tissue from normal donors was challenged  in vitro with increasing non-toxic 
concentrations of the irritant SDS (2 mM and 4 mM) or with vehicle (H2O). As shown in figure 
5, 2 mM SDS did not affect IL-1β, IL-1Ra, IL-36α, IL-36β, IL-36γ or IL-36Ra expression, 
whereas exposure to 4 mM SDS enhanced IL-33 expression (p<0.05). The latter result suggests 
that, in contrast to other members of IL-1 family, IL-33 mRNA can be stimulated by an irritant 
compound besides by allergens. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. mRNA expression of IL-1 family members in skin from normal donors treated with the vehicle (H2O) or 
SDS (2 mM and 4 mM). PCR values expressed relative to the housekeeping gene 18S. Data are displayed as boxes 
with the top and bottom representing the 25th and 75th percentiles, respectively; the line in the box represents the 
median and whiskers representing min and max. Error bars are not indicated when too small to depict. *p<0.05. 
 
 
 18 
3.5. Ex vivo anti-inflammatory activity of IL-36Ra 
Above we report that the mRNA of several members of the IL-1 family (IL-36α, IL-36β, IL-
36γ) was constitutively increased in lesional skin of ACD patients, but not the mRNA of their 
receptor antagonist IL-36Ra (Fig. 2). To evaluate whether lack of this negative regulation could 
be involved in ACD, we injected 50 µl of rIL-36Ra or the vehicle PBS in the skin biopsy of 
uninvolved skin of ACD patients and challenged the tissue with the appropriate allergen. We 
then assessed the mRNA levels of the pro-inflammatory members of the IL-1 family (IL-36α, 
IL-36β, IL-36γ). We also evaluated IL-8 mRNA, which is known to be induced by the former 
cytokines (Johnston et al., 2011). Figure 6 shows that injection of rIL-36Ra caused a decrease of 
IL-36α, IL-36β, IL-36γ and IL-8 mRNA expression compared with PBS-injected skin. These 
results suggest that rIL-36Ra can modulate the expression of  pro-inflammatory members of IL-
1 family in this in vitro model.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. mRNA expression of IL-36α, IL-36β, IL-36γ and IL-8 in uninvolved skin biopsy from ACD patients 
injected with recombinant rIL-36Ra (50 µl) or PBS and then challenged with the appropriate allergen for 72 h. PCR 
values expressed relative to the housekeeping gene 18S. Data are displayed as mean ± standard deviation. Error 
bars are not indicated when too small to depict. *p<0.05.  
 19 
3.6. IL-1Ra and IL-36Ra expression in peripheral blood mononuclear cells following 
nickel stimulation 
Given the inhibitory effects of IL-36Ra on certain IL-1 cytokines (Sims, Smith, 2010) and the 
present finding that it was not increased in ACD skin, we investigated the gene expression of 
two anti-inflammatory members of IL-1 family (IL-1Ra, IL-36Ra) in circulating PBMC. PBMC 
isolated from ACD patients with a positive patch test to NiSO4 and from healthy donors were 
exposed in vitro to NiSO4. Figure 7 shows that NiSO4 did not modify IL-1Ra or IL-36Ra 
mRNAs in PBMC of normal donors. By contrast, NiSO4 increased IL-1Ra, but not IL-36Ra 
mRNA expression, in PBMC of ACD patients.  
 
 
 
 
 
 
 
 
 
 
Figure 7. mRNA expression of IL-1Ra and IL-36Ra in PBMC of healthy adults (Control PBMC) and of patients 
with contact allergy to nickel (ACD PBMC) stimulated with NiSO4. PCR values expressed relative to the 
housekeeping gene 18S. Data are displayed as mean ± standard deviation. Error bars are not indicated when too 
small to depict. *p<0.05.  
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3.7. Ex vivo IL-33 activity  
Above we report that IL-33 mRNA is increased after challenge with allergen (Fig. 4) or 4 mM 
SDS (Fig. 4). To verify these results, we carried out immunohistochemical staining of skin from 
healthy donors topically exposed to SDS (4 mM). IL-33 was up-regulated in the basal layers of 
healthy skin treated with SDS (control + SDS) (Fig. 8a). To determine the relative contribution 
of IL-33 to skin inflammation in ACD, we investigated whether its neutralization could 
influence the local inflammatory milieu in ACD. We injected a neutralizing anti-IL-33 antibody 
(50 µl) or vehicle PBS in uninvolved skin biopsies cultured ex vivo before topical exposure to 
the specific allergen. Figure 8b shows that intradermal injection of PBS does not modify the 
expression of IL-8 or MCP-1 mRNA. By contrast, anti-IL-33 decreased allergen-induced 
expression of IL-8 mRNA. No changes were observed regarding MCP-1/CCL2 mRNA.  
 
 
Figure 8. (a) Immunohistochemical detection of IL-33 in skin from normal donors treated with SDS 4 mM 
(Control + SDS). Images X250 magnification. (b) Expression of IL-8 and MCP-1 mRNAs in uninvolved skin of 
ACD patients injected with PBS or anti-IL-33 antibody (50 µl) and then challenged with the appropriate allergen 
for 72 h. PCR values expressed relative to the housekeeping gene 18S. Data are displayed as mean ± standard 
deviation. Error bars are not indicated when too small to depict. *p<0.05. 
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4. DISCUSSION 
Skin inflammation in ACD is driven by the coordinated action of a wide spectrum of cytokines, 
including IL-1 family members (Kaplan et al., 2012). IL-36α (Smith et al., 2000), IL-36β 
(Smith et al., 2000, Kumar et al., 2000), IL-36γ (Kumar et al., 2000, Busfield et al., 2000) and 
IL-36Ra (Mulero et al., 1999, Smith et al., 2000), together with their receptor IL-36R, form a 
novel distinct IL-1 signalling system. Moreover, IL-33 is the most recent addition to the IL-1 
family and has potent immune-modulating properties that are mediated by the downstream 
induction of cytokines and chemokines (Ohno et al., 2011). Given the possible involvement of 
these new members of the IL-1 family in skin inflammation, we investigated their involvement 
in human ACD.  
We first analyzed skin biopsy specimens obtained from the involved skin of ACD patients, and 
found that IL-1β, IL-1Ra, IL-36α, IL-36β, IL-36γ and IL-33 mRNA was over-expressed 
compared to skin from normal donors. These results were extended at protein level by 
immunohistochemical examination of biopsies of involved skin of ACD patients. The results 
demonstrated up-regulation of IL-36α, IL-36β and IL-36γ, but not of IL-36Ra, compared to 
control skin. 
Ex vivo skin culture is a widely used technique that enables close monitoring of the events 
following activation and suppression of the immune system in human skin (Steinstraesser et al., 
2009). Using this experimental model we found that, after ex vivo challenge, the same IL-1 
family members (IL-1β, IL-1Ra, IL-36α, IL-36β, IL-36γ and IL-33) were over-expressed in the 
uninvolved skin of ACD patients versus the skin of normal donors.  
The development of ACD crucially depends on providing appropriate ‘danger’ signals to LC 
(Ouwehand et al., 2008), which are the main IL-1β producers (Enk et al., 1993). Allergen 
challenge rapidly increases IL-1β mRNA in mouse skin following topical application of the 
contact hapten (Kermani et al., 2000). This finding supports the hypothesis that IL-1β plays an 
initial role in skin sensitization. In addition, IL-1β induces keratinocyte production of TNF-α, 
 22 
which induces LC migration (Cumberbatch et al., 1997). Other investigators have argued that in 
a contact hypersensitivity murine model (IL-1F2-null mouse), IL-1β alone was not essential, 
which suggests that IL-36γ is involved in contact hypersensitivity (Kumar et al., 2000). Here we 
demonstrate, both in vivo and ex vivo, that besides IL-1β, also IL-36α, IL-36β and IL-36γ are 
over-expressed in ACD skin. 
IL-33 is constitutively expressed in epidermal keratinocytes and its expression is up-regulated 
by inflammatory stimuli such as TNF-α or lipopolysaccharides (Schmitz et al., 2005). 
Keratinocytes are positioned in contact with the environment and IL-33 might function as an 
early warning system at sites of skin inflammation (Dickel et al., 2010). In this study we found 
constitutive over-expression of IL-33 mRNA in involved skin of ACD patients and in ex vivo 
healthy skin topically exposed to the irritant SDS. These results are consistent with the 
hypothesis that this cytokine acts as an endogenous warning signal mediating the recruitment of 
innate immune cells to sites of skin inflammation (Smith, 2010). Our findings extend recent 
results indicating IL-33 is a danger signal produced in response to tissue damage and UVB 
(Byrne et al., 2011, Moussion et al., 2008). Interestingly, intradermal injection of anti-IL-33 
caused inhibition of IL-8 mRNA, but not of MCP-1/CCL2. IL-8 is involved in ACD as well as 
in irritancy by exerting chemotactic activity on neutrophils and monocytes (Collington et al., 
2010, Spiekstra et al., 2005). Suppression of IL-8 ex vivo by neutralization of IL-33 reinforces 
the concept that IL-33 acts as an “alarmin”. 
The IL-1 family includes two inhibitory cytokines: IL-1Ra and IL-36Ra (Sims et al., 2010). IL-
1Ra competes with IL-1α and IL-1β for binding to IL-1R (Eisenberg et al., 1991), whereas IL-
36Ra competes with IL-36α, IL-36β and IL-36γ for binding to IL-36R (Towne et al., 2004). We 
found that IL-1Ra is over-expressed in ACD skin, whereas IL-36Ra is not. We obtained similar 
findings in peripheral blood of nickel-sensitized patients challenged in vitro with the allergen. 
These results highlight a different pattern of expression of two antagonistic IL-1 cytokines in 
ACD, which suggests that they may modulate cutaneous inflammation differently.  
 23 
Injection of recombinant human IL-36Ra into involved skin explants of ACD patients caused 
inhibition of IL-36α, IL-36β, IL-36γ and IL-8 mRNAs. These results might indicate that a lack 
of over-expression of IL-36Ra could be, at least in part, responsible for the over-expression of 
IL-36α, IL-36β, IL-36γ in ACD patients. Over-expression of IL-36α, IL-36β and IL-36γ in the 
skin of ACD patients can induce Th-17 cytokines that participate in the physiopathology of 
ACD (Zhao et al., 2009). The role of IL-36s and IL-36Ra in ACD is also supported by 
experiments conducted with transgenic mice deficient in IL-36Ra (Blumberg et al., 2007). 
In conclusion, our results highlight the complexity of the involvement of pro-inflammatory and 
antagonistic members of the IL-1 family in the pathogenesis of ACD. In particular we found an 
over-expression at both molecular and protein level of IL-1β and IL-36α, IL-36β, IL-36γ in the 
skin of ACD patients where these cytokines can play a pro-inflammatory role. We also detected 
over-expression of IL-33 in both allergic and irritant conditions suggesting that this cytokine 
might function as an early warning system at the site of skin damage. While IL-1Ra was 
increased in ACD skin, IL-36Ra was unchanged, which suggests that the activity of IL-36α, IL-
36β and IL-36γ is “unopposed” and therefore that these cytokines can drive skin inflammation. 
This observation prompts the speculation that IL-36Ra might be a candidate for ACD therapy.  
This study has started to shed light on the complexity of the possible interactions among 
different agonistic and antagonistic members of the IL-1 family in ACD. The characterization of 
the roles of these cytokines in skin inflammation in ACD requires additional experiments. 
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